Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

glucocorticoid-induced osteoporosis - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

glucocorticoid-induced osteoporosis

MONDO:0000757

Also known as:steroid-induced osteoporosis

Find Clinical TrialsTrials

Overview

An osteoporosis caused by chronic glucocorticoid use. Glucocorticoids impair the replication, differentiation and function of osteoblasts and induce the apoptosis of mature osteoblasts and osteocytes; the also favor osteoclastogenesis leading to an increase in bone resorption.

Treatments7 FDA approved, newest 2025

Clinical Trials4 registered · 1 recruiting

Diagnosis

Biomarker and diagnostic research for glucocorticoid-induced osteoporosis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

4 FDA-approved treatments are available for glucocorticoid-induced osteoporosis, including DENOSUMAB (CONEXXENCE, approved 2025), ALENDRONATE SODIUM (FOSAMAX, approved 1995), and DENOSUMAB-MOBZ (BONCRESA, approved 2025).

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

4 clinical trials registered, 1 recruiting. Interventions under study include drug therapy. Pipeline includes 3 PHASE4. Research is sponsored by a mix of industry and academic institutions.

201 publications have been identified in PubMed for glucocorticoid-induced osteoporosis. Research spans Basic Science / Preclinical (49%), Review / Meta-Analysis (17%), and Epidemiology / Natural History (14%).

Research Type	Count	% of Total
Laboratory research	98

Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 3:59 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→What are the benefits and potential side effects of CONEXXENCE for managing glucocorticoid-induced osteoporosis?
→Are any of the 4 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

glucocorticoid-induced osteoporosis

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications